AAPL   319.12 (+0.27%)
MSFT   181.87 (+0.26%)
FB   224.90 (-0.25%)
GOOGL   1,425.71 (+0.53%)
AMZN   2,410.03 (+0.37%)
NVDA   345.48 (+1.77%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
MU   47.37 (+1.94%)
GE   6.54 (-3.68%)
TSLA   819.80 (+1.74%)
AMD   52.57 (+1.60%)
T   30.55 (-1.67%)
ACB   13.96 (-9.00%)
F   5.66 (-3.25%)
GILD   75.02 (-0.32%)
NFLX   413.21 (-0.06%)
BAC   24.45 (-1.65%)
BA   144.35 (-3.65%)
AAPL   319.12 (+0.27%)
MSFT   181.87 (+0.26%)
FB   224.90 (-0.25%)
GOOGL   1,425.71 (+0.53%)
AMZN   2,410.03 (+0.37%)
NVDA   345.48 (+1.77%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
MU   47.37 (+1.94%)
GE   6.54 (-3.68%)
TSLA   819.80 (+1.74%)
AMD   52.57 (+1.60%)
T   30.55 (-1.67%)
ACB   13.96 (-9.00%)
F   5.66 (-3.25%)
GILD   75.02 (-0.32%)
NFLX   413.21 (-0.06%)
BAC   24.45 (-1.65%)
BA   144.35 (-3.65%)
AAPL   319.12 (+0.27%)
MSFT   181.87 (+0.26%)
FB   224.90 (-0.25%)
GOOGL   1,425.71 (+0.53%)
AMZN   2,410.03 (+0.37%)
NVDA   345.48 (+1.77%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
MU   47.37 (+1.94%)
GE   6.54 (-3.68%)
TSLA   819.80 (+1.74%)
AMD   52.57 (+1.60%)
T   30.55 (-1.67%)
ACB   13.96 (-9.00%)
F   5.66 (-3.25%)
GILD   75.02 (-0.32%)
NFLX   413.21 (-0.06%)
BAC   24.45 (-1.65%)
BA   144.35 (-3.65%)
AAPL   319.12 (+0.27%)
MSFT   181.87 (+0.26%)
FB   224.90 (-0.25%)
GOOGL   1,425.71 (+0.53%)
AMZN   2,410.03 (+0.37%)
NVDA   345.48 (+1.77%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
MU   47.37 (+1.94%)
GE   6.54 (-3.68%)
TSLA   819.80 (+1.74%)
AMD   52.57 (+1.60%)
T   30.55 (-1.67%)
ACB   13.96 (-9.00%)
F   5.66 (-3.25%)
GILD   75.02 (-0.32%)
NFLX   413.21 (-0.06%)
BAC   24.45 (-1.65%)
BA   144.35 (-3.65%)
Log in

OTCMKTS:CVSICV Sciences Stock Price, Forecast & News

$0.88
0.00 (0.00 %)
(As of 05/29/2020 01:19 PM ET)
Add
Compare
Today's Range
$0.72
Now: $0.88
$0.97
50-Day Range
$0.40
MA: $0.57
$1.18
52-Week Range
$0.25
Now: $0.88
$4.94
Volume2.70 million shs
Average Volume1.60 million shs
Market Capitalization$87.87 million
P/E RatioN/A
Dividend YieldN/A
Beta0.06
CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. This segment provides its hemp extract products in balms, sprays, drops, capsules, gummies, and softgel forms. It also sells raw materials to various customers that produce products for resale into the market in Europe. The Specialty Pharmaceuticals segment develops cannabinoids to treat a range of medical indications. Its product candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.93 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CVSI
Previous SymbolNASDAQ:CVSI
CUSIPN/A
Phone866-290-2157

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.70 million
Book Value$0.25 per share

Profitability

Net Income$-16,610,000.00

Miscellaneous

Employees78
Market Cap$87.87 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive CVSI News and Ratings via Email

Sign-up to receive the latest news and ratings for CVSI and its competitors with MarketBeat's FREE daily newsletter.

CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions

How has CV Sciences' stock been impacted by COVID-19 (Coronavirus)?

CV Sciences' stock was trading at $0.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CVSI stock has increased by 46.7% and is now trading at $0.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CV Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CV Sciences.

When is CV Sciences' next earnings date?

CV Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for CV Sciences.

How were CV Sciences' earnings last quarter?

CV Sciences Inc (OTCMKTS:CVSI) posted its quarterly earnings results on Friday, May, 8th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.02. The business had revenue of $8.27 million for the quarter, compared to the consensus estimate of $6 million. CV Sciences had a negative return on equity of 40.55% and a negative net margin of 26.31%. View CV Sciences' earnings history.

What price target have analysts set for CVSI?

3 equities research analysts have issued 12-month price targets for CV Sciences' shares. Their forecasts range from $1.70 to $5.00. On average, they anticipate CV Sciences' stock price to reach $3.35 in the next twelve months. This suggests a possible upside of 280.7% from the stock's current price. View analysts' price targets for CV Sciences.

Has CV Sciences been receiving favorable news coverage?

Headlines about CVSI stock have trended positive on Friday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. CV Sciences earned a news sentiment score of 2.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the next several days. View the latest news aboutCV Sciences.

Who are some of CV Sciences' key competitors?

What other stocks do shareholders of CV Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), KushCo (KSHB), Aphria (APHA), OrganiGram (OGI), Tilray (TLRY), GW Pharmaceuticals PLC- (GWPH) and Medical Marijuana (MJNA).

Who are CV Sciences' key executives?

CV Sciences' management team includes the following people:
  • Mr. Joseph D. Dowling, CEO, Sec. & Director (Age 62)
  • Mr. Michael J. Mona III, Co-Founder, COO & Director (Age 33)
  • Mr. Joerg Grasser, CFO, Chief Accounting Officer & Director
  • Dr. Joseph Maroon, MD & Director
  • Dr. Douglas MacKay ND, Sr. VP of Scientific & Regulatory Affairs and Director

What is CV Sciences' stock symbol?

CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."

How do I buy shares of CV Sciences?

Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CV Sciences' stock price today?

One share of CVSI stock can currently be purchased for approximately $0.88.

How big of a company is CV Sciences?

CV Sciences has a market capitalization of $87.87 million and generates $53.70 million in revenue each year. The company earns $-16,610,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. CV Sciences employs 78 workers across the globe.

What is CV Sciences' official website?

The official website for CV Sciences is www.cvsciences.com.

How can I contact CV Sciences?

CV Sciences' mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 866-290-2157 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.